Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor pathways.
Tempest Therapeutics has raised $2.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2026.
Tempest Therapeutics's investors include Lilly Asia Ventures, Foresite Capital, New Enterprise Associates, Quan Capital, Versant Ventures.
Tempest Therapeutics is headquartered in San Francisco, United States.
Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor pathways.
Tempest Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tempest Therapeutics — Funding & Investors." VCBacked, May 29, 2026, https://www.vcbacked.co/company/tempest-therapeutics. Accessed July 19, 2026.
VCBacked. (2026). Tempest Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/tempest-therapeutics
{{cite web |title=Tempest Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tempest-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated